Data / Form D filings / Braeburn Pharmaceuticals, Inc.
Braeburn Pharmaceuticals, Inc.: Form D filing
Braeburn Pharmaceuticals, Inc., a biotechnology company in Princeton, NJ, filed a Form D with the SEC in 2018. The latest, on January 19, 2018, reports $110 million sold of a $110 million offering to 8 investors.
Find out what Braeburn Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 47 HULFISH STREET, SUITE 441, Princeton, NJ, 08542
- Phone
- (609) 751-5375
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1688765
The full lists. Form D filings in New Jersey: 714 rows, $35.70, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 19, 2018 | New notice | $110,003,471 | $110,003,471 | $0 | 8 | Jan 8, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Dennis H. Langer, J. D., M.D. | Director | |
| Jeffrey L. Berkowitz | Director | |
| David J. McIntyre | Executive Officer | |
| Asher M. Rubin | Executive Officer | |
| Brian H. Markison | Director | |
| Argeris L. Karabelas, Ph.D. | Director | |
| Patrick L. Kennedy | Director | |
| Michael Derkacz | Executive Officer, Director | |
| Seth L. Harrison, M.D. | Executive Officer, Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
Every Form D from the week of Jan 15, 2018 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Braeburn Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.